Loading clinical trials...
Loading clinical trials...
MATCH Treatment Subprotocol U: VS-6063 (Defactinib) in Patients With Tumors With NF2 Loss
Conditions
Interventions
Defactinib Hydrochloride
Locations
1
United States
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, United States
Start Date
November 19, 2015
Primary Completion Date
November 10, 2020
Completion Date
January 15, 2027
Last Updated
April 13, 2026
NCT05969860
NCT05101213
NCT04879121
NCT04565665
NCT03907475
NCT05053971
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions